Clinical trials: Neoplasms, Ovarian
Cancer, Risk of Premature Ovarian Failure
Cryopreservation of Ovarian Tissue
The study hopes to contribute to the development of technologies of ovarian tissue freezing-thawing and in vitro maturation of immature eggs such that a person at risk for premature ovarian failure might be able to conceive a…
- Conditions
- Cancer, Risk of Premature Ovarian Failure, Fertility Preservation
- Trial name
- NCT01558544
- Testing
- surgery to remove ovaries or high dose chemotherapy
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Weill Medical College of Cornell University
Newly Diagnosed, Advanced Ovarian Cancer
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy.
- Conditions
- Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
- Trial name
- SOLO-1 (NCT01844986)
- Testing
- Olaparib 300mg tablets
- Where
- 177 sites in United States, Australia and 13 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Early Stage Ovarian Tumors, Peritoneal Carcinosis
PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors
Early-stage ovarian tumors represent approximately 30% of all newly diagnosed ovarian cancers. Current international guidelines recommend random peritoneal biopsies for surgical staging, but the diagnostic yield of these biopsies…
- Trial name
- PONDER (NCT07271914)
- Testing
- systematic surgical approach to wider peritoneal biopsies according with dissection of retroperitoneal spaces, nerve-sparing approach, Histopathologic Analysis
- Where
- Italy
- Volunteers
- 390 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Ovarian Neoplasms, Peritoneal Neoplasms
Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the tolerance, safety, efficacy, and pharmacokinetics of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with paclitaxel in patients with platinum-resistant recurrent ovarian…
- Trial name
- NCT07273396
- Testing
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC) using paclitaxel
- Volunteers
- 53 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer, Fallopian Tube Cancers
Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance
The goal of this retrospective observational study is to evaluate the relationship between different dietary patterns (specifically low-carbohydrate diets) and the prognosis of patients with high-grade serous ovarian cancer…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Carcinoma, High-grade Serous Ovarian Cancer
- Trial name
- NCT07269574
- Volunteers
- 600 people
- Sponsor
- Tongji Hospital
Ovarian Carcinoma, Cervical Carcinoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Multicenter ambispective observational study (prospective/retrospective)
- Conditions
- Ovarian Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Vulvar Carcinoma
- Trial name
- NCT07267780
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer, Non Small Cell Lung Cancer
Minimal Residual Disease in Solid Malignancies
The IMRD study is a single-centre, prospective observational study which will investigate the rate of ctDNA (circulating tumor DNA) detection from the start of adjuvant therapy following curative-intent surgery.
- Conditions
- Breast Cancer, Non Small Cell Lung Cancer, Prostate Cancer, High Grade Serous Ovarian Cancer
- Trial name
- IMRD (NCT07268469)
- Testing
- ctDNA detection
- Volunteers
- 840 people
- Sponsor
- European Institute of Oncology
Ovarian Cancer, Surgery
PROADAPT-ovary/EWOC-2
PROADAPT is a standardized geriatric intervention that is currently being co-constructed during an exploratory phase on a multi-professional and multi-disciplinary basis after a systematic analysis of published data (Figure).
- Trial name
- NCT04284969
- Testing
- PROADAPT program
- Where
- 11 sites in France
- Volunteers
- 292 people
- Sponsor
- Hospices Civils de Lyon
Gynecological Tumor, Ovarian Cancer
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignancies, yet chemotherapy-induced…
- Conditions
- Gynecological Tumor, Ovarian Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT06007586
- Testing
- Aprepitant Injection
- Where
- 2 sites in China
- Volunteers
- 143 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection
Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment
This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.
- Conditions
- Cancer-related Cognitive Dysfunction, Cytomegaloviral Infection, Fallopian Tube Carcinoma, Ovarian Carcinoma
- Trial name
- NCT06870539
- Testing
- Non-Interventional Study
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
The target populations for this phase I study with TBI-1301 are patients with advanced solid tumors. Patients' tumors will be required to express NY-ESO-1, which include but is not limited to ovarian cancer, synovial sarcoma…
- Conditions
- NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma, Melanoma, Esophageal Cancer
- Trial name
- NCT02869217
- Testing
- Cyclophosphamide, TBI-1301, Fludarabine
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer
Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer
This is a randomized, open, comparative, multi-centre study which will recruit up to 66 patients. The objective is mainly to explore the safety and feasibility in neo-adjuvant first-line ovarian cancer (including patients with…
- Trial name
- INeOV (NCT03249142)
- Testing
- ARM A Durvalumab/chemotherapy association, ARM B Durvalumab/Tremelimumab/chemotherapy association
- Where
- 11 sites in France
- Volunteers
- 69 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Tumor, Ovarian Cancer
Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian cancer is the fifth leading cause of cancer death in women worldwide. Most of these cancers are manifested in the form of an ovarian cyst. Practitioners are faced with two main difficulties.
- Trial name
- TORCH (NCT02326064)
- Where
- 4 sites in France
- Volunteers
- 221 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
ER+ Breast Cancer, Ovarian Cancer
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
This Phase 1b is a dose escalation, MTD expansion and cohort expansions study to assess the safety and tolerability of a combination of NAP with durvalumab in subjects with selected advanced or metastatic solid tumors.
- Conditions
- ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT03983954
- Testing
- Obinutuzumab, naptumomab estafenatox and durvalumab, Naptumomab estafenatox and durvalumab
- Where
- 9 sites in India, Israel
- Volunteers
- 120 people
- Sponsor
- NeoTX Therapeutics Ltd.
Small Cell Ovarian Carcinoma
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT
Small cell ovarian carcinomas are rare and have a very poor prognosis affecting a young population. The objective of this study is to increase the efficacy of the initial chemotherapy by providing immunotherapy and to be able to…
- Trial name
- PembroSCCOHT (NCT04602377)
- Testing
- Pembrolizumab 25 MG/ML [Keytruda]
- Where
- 13 sites in France
- Volunteers
- 27 people
- Sponsor
- ARCAGY/ GINECO GROUP
Advanced Solid Tumors, HR+ Breast Cancer
(VELA) Study of BLU-222 in Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
- Conditions
- Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer
- Trial name
- NCT05252416
- Testing
- BLU-222, Carboplatin, Ribociclib
- Where
- 23 sites in United States, Italy and 1 more
- Volunteers
- 50 people
- Sponsor
- Blueprint Medicines Corporation
Ovarian Neoplasms
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC).
- Trial name
- NCT06964165
- Testing
- Niraparib, Carboplatin, Paclitaxel
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Tesaro, Inc.
Genetic Predisposition to Disease
Breast Cancer Risk After Diagnostic Gene Sequencing
Study of the psychological impact of breast cancer risk communication in Cancer Genetics based on the personalized estimation of the BOADICEA V5/PLUS model ("Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation…
- Trial name
- BRIDGEScohort2 (NCT04145817)
- Testing
- BRIDGES gene panel testing, Breast cancer risk polygenic risk score (PRS), Questionnaires
- Where
- 2 sites in France, Germany
- Volunteers
- 405 people
- Sponsor
- Institut Curie
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK